Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14281128 | 1.00 | LTA4H (0.45) | LTA4HFAAHNOD1ALDH1A1CA1 | |
| SCHEMBL8653509 | 0.89 | FAAH (0.41) | LTA4HFAAHNOD1ALDH1A1MMP2 | |
| SCHEMBL29783052 | 0.87 | NOD1 (0.48) | LTA4HFAAHNOD1ALDH1A1 | |
| SCHEMBL16976936 | 0.87 | NOD1 (0.48) | LTA4HFAAHNOD1ALDH1A1 | |
| SCHEMBL4450429 | 0.87 | NOD1 (0.48) | LTA4HFAAHNOD1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29783202 | 0.86 | NOD1 (0.47) | LTA4HFAAHNOD1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29783043 | 0.86 | NOD1 (0.47) | LTA4HFAAHNOD1ALDH1A1 | |
| SCHEMBL5325285 | 0.84 | NOD1 (0.39) | LTA4HFAAHNOD1ALDH1A1MMP2 | |
| SCHEMBL6782544 | 0.83 | LTA4H (0.47) | LTA4HFAAHNOD1ALDH1A1 | |
| SCHEMBL16381809 | 0.82 | LTA4H (0.46) | LTA4HFAAHNOD1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103690529-A | Application of methyl coumarin-3-carboxylyl L-theanine and the like in preparation of product used for preventing and treating disease such as cancers | UNIV YANTAI | 2014-04-02 | — | — | CN | claimed |
| EP-2902388-B1 | CONDENSATION PRODUCT OF THEANINE DERIVATIVE AND CARBOXYLIC ACID COUMARIN DERIVATIVE, INTERMEDIATE OF THE CONDENSATION PRODUCT, METHOD FOR PREPARING SAME, AND USE THEREOF | SHANDONG YINGDONG YINGHAO BIOTECHNOLOGY INC (CN) | 2019-03-13 | — | — | EP | disclosed |
| US-9518038-B2 | Condensation product of theanine derivative and carboxylic acid coumarin derivative, its intermediate, preparation method and use thereof | SHANDONG YINGDONG YINGHAO BIOTECHNOLOGY, INC. (CN) | 2016-12-13 | — | — | US | disclosed |
| US-9518038-B2 | Condensation product of theanine derivative and carboxylic acid coumarin derivative, its intermediate, preparation method and use thereof | SHANDONG YINGDONG YINGHAO BIOTECHNOLOGY, INC. (CN) | 2016-12-13 | — | — | US | disclosed |
| US-9518038-B2 | Condensation product of theanine derivative and carboxylic acid coumarin derivative, its intermediate, preparation method and use thereof | SHANDONG YINGDONG YINGHAO BIOTECHNOLOGY, INC. (CN) | 2016-12-13 | — | — | US | disclosed |
| US-20150239861-A1 | CONDENSATION PRODUCT OF THEANINE DERIVATIVE AND CARBOXYLIC ACID COUMARIN DERIVATIVE, ITS INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | ZHANG, GUOYING (CN) | 2015-08-27 | — | — | US | disclosed |
| US-20150239861-A1 | CONDENSATION PRODUCT OF THEANINE DERIVATIVE AND CARBOXYLIC ACID COUMARIN DERIVATIVE, ITS INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | ZHANG, GUOYING (CN) | 2015-08-27 | — | — | US | disclosed |
| US-20150239861-A1 | CONDENSATION PRODUCT OF THEANINE DERIVATIVE AND CARBOXYLIC ACID COUMARIN DERIVATIVE, ITS INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | ZHANG, GUOYING (CN) | 2015-08-27 | — | — | US | disclosed |
| EP-2902388-A1 | CONDENSATION PRODUCT OF THEANINE DERIVATIVE AND CARBOXYLIC ACID COUMARIN DERIVATIVE, INTERMEDIATE OF THE CONDENSATION PRODUCT, METHOD FOR PREPARING SAME, AND USE THEREOF | Yantai University (CN) | 2015-08-05 | — | — | EP | disclosed |
| EP-2902388-A1 | CONDENSATION PRODUCT OF THEANINE DERIVATIVE AND CARBOXYLIC ACID COUMARIN DERIVATIVE, INTERMEDIATE OF THE CONDENSATION PRODUCT, METHOD FOR PREPARING SAME, AND USE THEREOF | Yantai University (CN) | 2015-08-05 | — | — | EP | disclosed |
| CN-103052634-B | Theanine derivatives, their preparation and use for alleviating acne | AMOREPACIFIC CORP | 2014-12-31 | — | — | CN | disclosed |
| EP-2604605-B1 | THEANINE DERIVATIVE, PREPARATION METHOD THEREOF, AND USE THEREOF FOR ALLEVIATING ACNE | AMOREPACIFIC CORP (KR) | 2014-12-24 | — | — | EP | disclosed |
| CN-104144919-A | CONDENSATION PRODUCT OF THEANINE DERIVATIVE AND CARBOXYLIC ACID COUMARIN DERIVATIVE, INTERMEDIATE OF THE CONDENSATION PRODUCT, METHOD FOR PREPARING SAME, AND USE THEREOF | WUWEI COUNTY MARINE BIOTECHNOLOGY CO LTD | 2014-11-12 | — | — | CN | disclosed |
| CN-103690529-A | Application of methyl coumarin-3-carboxylyl L-theanine and the like in preparation of product used for preventing and treating disease such as cancers | UNIV YANTAI | 2014-04-02 | — | — | CN | disclosed |
| US-8557793-B2 | Theanine derivative, preparation method thereof, and use thereof for alleviating acne | AMOREPACIFIC CORPORATION (KR) | 2013-10-15 | — | — | US | disclosed |
| EP-2604605-A2 | THEANINE DERIVATIVE, PREPARATION METHOD THEREOF, AND USE THEREOF FOR ALLEVIATING ACNE | Amorepacific Corporation (KR) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137653-A1 | THEANINE DERIVATIVE, PREPARATION METHOD THEREOF, AND USE THEREOF FOR ALLEVIATING ACNE | AMOREPACIFIC CORPORATION (KR) | 2013-05-30 | — | — | US | disclosed |
| CN-103052634-A | Theanine derivatives, their preparation and use for alleviating acne | AMOREPACIFIC CORP | 2013-04-17 | — | — | CN | disclosed |
| WO-2012020966-A2 | THEANINE DERIVATIVE, PREPARATION METHOD THEREOF, AND USE THEREOF FOR ALLEVIATING ACNE | (주)아모레퍼시픽 (KR) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137653-A1 | THEANINE DERIVATIVE, PREPARATION METHOD THEREOF, AND USE THEREOF FOR ALLEVIATING ACNE | CUTA, NOTUM, HAGH | LTA4H 710/4885FAAH 1502/4885NOD1 1376/4885 |
| US-20150239861-A1 | CONDENSATION PRODUCT OF THEANINE DERIVATIVE AND CARBOXYLIC ACID COUMARIN DERIVATIVE, ITS INTERMEDIATE, PREPARATION METHOD AND USE THEREOF | OGDH, C9, IRAK3 | LTA4H 2625/4885FAAH 2001/4885NOD1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.